Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025
home / post-conference-perspectives / evolving-immunotherapy-in-myeloma-insights-on-bispecific-and-trispecific-antibodies-from-asco
Episodes
June 17th 2025EP. 1: Setting the Stage and New Milestones in Talquetamab Data
A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer durability with biweekly dosing, including in patients previously treated with B-cell maturation antigen–targeted therapies, supporting sequencing and combination strategies to improve outcomes.
